Beijing Meifuyuan Biomedical Technology Co., Ltd.

To investigate the safety and tolerability of single and multiple doses of this product as well as its pharmacokinetic and pharmacodynamic indicators in patients with chronic hepatitis B, and to explore its preliminary clinical efficacy in the treatment of chronic hepatitis B.

To evaluate the efficacy and safety of recombinant human serum albumin/granulocyte stimulating factor fusion protein for injection in preventing chemotherapy-induced neutropenia and to provide a basis for safe and effective dosing regimens in phase III clinical trials.

To evaluate the tolerability and safety of breast cancer patients after receiving single and multiple injections of different doses of recombinant human serum albumin/granulocyte stimulating factor fusion protein, and provide a basis for the dosing regimen of phase II clinical trials. To observe the pharmacokinetic characteristics of recombinant human serum albumin/granulocyte stimulating factor fusion protein after single and multiple administrations.